Acquisition Synergy AIT Bioscience is now part of Nexelis, expanding access to bioanalytical LC/MS and ligand binding capabilities within a larger portfolio, presenting cross-sell opportunities to Nexelis’ existing pharmaceutical clients and expanding service footprint.

Small to Large Molecule With strengths across small and large molecule testing, target sponsors across biotech and pharma development stages seeking integrated bioanalytical solutions can be approached for expanded testing programs and partner outsourcing.

Digital Infrastructure Existing ELN adoption and a modern tech stack (WordPress, HubSpot, Salesforce, Dynamics) indicate readiness for streamlined customer engagement, digital marketing outreach, and scalable CRM-driven sales campaigns.

Growth Momentum Historical growth through Nexelis acquisitions and asset investments signals an ongoing expansion strategy; position opportunities around entering new therapies, geographies, or regulatory pathways aligned with Nexelis’ growth plan.

Mid-market Focus As a smaller CRO with 11-50 employees and revenue in the lower mid-market range, there is potential to pursue mid-sized sponsors seeking cost-efficient bioanalytical outsourcing, niche capabilities, and responsive project delivery.